MGMT, Recombinant, Human, Western Blot Control (O6-Methylguanine DNA Methyltransferase)

MGMT (O6-methylguanine-DNA methyltransferase). Many tumor promoting/causing agents (BCNU, CCNU, DTIC, procarbazine, temozolomide, etc) generate lethal cross-links at the O6-alkylguanine position in DNA. MGMT removes alkyl adducts from the O6-position of guanine in DNA (prior to cross-link formation) to its cysteine residue, thereby irreversibly inactivating MGMT. Inactivated MGMT is rapidly degraded. Therefore, MGMT levels serve as an indicator of DNA damage. Tumors with high level of MGMT are likely to be drug resistant and low or no MGMT may make the tumor more responsive to chemotherapy. In normal cells, abnormally low level of MGMT may make normal cells/tissue more susceptible to tumor promoting/alkylating agents.\n\nBiological Activity:\nBiologically inactive\n\nApplications:\nSuitable for use in Western Blot. Other applications not tested. \n\nRecommended Dilution:\nWestern Blot: Heat once and load 10ul/lane and visualize with M3884-91C & M3884-91E.\nOptimal dilutions to be determined by the researcher. \n\nStorage and Stability:\nLyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with sterile buffer or ddH2O. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 6 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

M3884-92D

Size

100ul

Applications

WB

Form

Supplied as a lyophilized powder from PBS, 0.05% sodium azide.

Purity

Purified

References

1. Von Wronski et al (1994) Carcinogenesis 15, 577-582 2. Harris LC et al 91992) 52, 6404-6406 3. Shimada Y (2003) Intl J Radiat Biol 79, 423-430 (WB) 4. Biswas T (1999) Oncogene 18, 525